Clinical Trials Logo

Clinical Trial Summary

This study aims at investigating the complications of Cushing's disease in "de novo" patients. A series of investigations will assay before treatment and every year thereafter during a 3 years follow-up period the various complications of the disease. These investigations will determine the presence and severity of cardiovascular, metabolic, and bone complications as well as the Quality of Life. Outcome of these complications after treatment, especially after pituitary surgery will be monitored, as well as cortisol levels.


Clinical Trial Description

At inclusion the following will be investigated and recorded :

- demographic and personal medical history.

- Familial medical history related to osteoporosis, cardiovascular disorders and thromboembolism.

- Current medical treatment.

- Physical examination.

- Assessment of basal 24hrs urinary cortisol and salivary cortisol.

- At baseline (i.e. before specific treatment of Cortisol excess):

- physical examination,

- routine biology,

- HbA1C, fasting glucose and oral glucose load,

- cholesterol, triglyceride, HDL & LDL,

- coagulation and fibrinolysis investigation,

- 24hrs urinary cortisol and salivary cortisol, urinary labstick test.

- EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US,

- ophthalmology examination,

- spine X-Ray, bone densitometry,

- QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).

Every year during a 3 years follow-up the following will be investigated :

- Current medical treatment.

- Physical examination.

- Assessment of basal routine biology,

- HbA1C, fasting glucose,

- cholesterol, triglyceride, HDL & LDL,

- coagulation and fibrinolysis investigation,

- 24hrs urinary cortisol and salivary cortisol, urinary labstick test.

- EKG, cardiac ultrasound, cardiac CT-scan (if abnormal initially), arterial and venous US,

- ophthalmology examination, bone densitometry,

- QoL questionnaires (SF-36, QoLCushing, Beck BDI-II). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02568982
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase
Start date September 21, 2015
Completion date December 20, 2019

See also
  Status Clinical Trial Phase
Terminated NCT00881283 - Long-term Cardiovascular Risk in Cured Cushing's Patients
Completed NCT02697734 - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Phase 3
Completed NCT01374906 - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Phase 3
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting NCT02603653 - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease N/A
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Recruiting NCT00845351 - Preoperative Bexarotene Treatment for Cushing's Disease Phase 1/Phase 2
Completed NCT00889525 - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Phase 3
Completed NCT02060383 - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Phase 4
Recruiting NCT04339751 - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Phase 2
Not yet recruiting NCT04569591 - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease N/A
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT02484755 - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Phase 2
Active, not recruiting NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT00434148 - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Phase 3
Completed NCT03346954 - Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease N/A
Withdrawn NCT01925092 - Mifepristone in Children With Refractory Cushing's Disease Phase 3
Completed NCT01582061 - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Phase 3
Recruiting NCT03708900 - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Phase 2
Terminated NCT00612066 - Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Phase 2